Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 3/2009

01.05.2009 | Original Article

Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys

verfasst von: Takeshi Manabe, Satoshi Mori, Tasuku Mashiba, Yongping Cao, Yoshio Kaji, Ken Iwata, Satoshi Komatsubara, Tetsuji Yamamoto, Azusa Seki, Hiromichi Norimatsu

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

We investigated the effect of eel calcitonin (elcatonin) on the process of fracture repair in the osteotomized femur of cynomolgus monkeys, since they possess a Haversian remodeling system similar to that of humans. Alendronate was used for comparison. Twenty female cynomolgus monkeys (Macaca fascicularis), aged 18–22 years, were allocated into five groups: control (CNT, n = 4), low-dose elcatonin group (0.5 U/kg; ELL, n = 4), high-dose elcatonin group (5 U/kg; ELH, n = 4), low-dose alendronate group (10 μg/kg; ALL, n = 4) and high-dose alendronate group (100 μg/kg; ALH, n = 4). All animals were given subcutaneous injections twice a week for 3 weeks. Then fracture was produced surgically by transversely cutting the midshaft of the right femur and fixing with stainless steel plate. After fracture, treatments were continued until sacrifice at 26 weeks after surgery. The femora were assessed by micro CT, contact microradiograph, three-point bending mechanical test and histomorphometry. Micro CT showed that callus sizes in elcatonin-treated groups were similar to CNT, whereas alendronate-treated groups had larger calluses than those in the CNT and elcatonin-treated groups. Fracture lines almost disappeared in the CNT and elcatonin-treated groups but remained clear in the alendronate-treated groups. Total area did not differ significantly between the elcatonin-treated groups and the CNT but was significantly greater in the ALH compared to the CNT and elcatonin-treated groups, due to increased callus area in the ALH group. Callus remodeling was less suppressed in the elcatonin-treated groups than in the alendronate-treated groups when compared with callus remodeling in the CNT. Although no significant differences in structural mechanical properties such as ultimate load, stiffness and work to failure were found among all groups, ultimate stress was significantly reduced in the ALH group compared with CNT and ELL groups. In conclusion, mild suppression of callus remodeling by elcatonin did not impair overall fracture healing process. In contrast, alendronate delayed structural fracture healing process by strongly suppressing callus remodeling.
Literatur
1.
Zurück zum Zitat Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696PubMedCrossRef Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696PubMedCrossRef
2.
Zurück zum Zitat Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106PubMedCrossRef Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106PubMedCrossRef
3.
Zurück zum Zitat Delmas PD (2002) Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30:14–17PubMedCrossRef Delmas PD (2002) Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30:14–17PubMedCrossRef
5.
Zurück zum Zitat Fleisch H (2001) Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16:437–440PubMedCrossRef Fleisch H (2001) Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16:437–440PubMedCrossRef
6.
7.
Zurück zum Zitat Fujita T, Fujii Y, Miyauchi A, Takagi Y (1999) Comparison of antiresoptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin. J Bone Miner Metab 17:289–295PubMedCrossRef Fujita T, Fujii Y, Miyauchi A, Takagi Y (1999) Comparison of antiresoptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin. J Bone Miner Metab 17:289–295PubMedCrossRef
8.
Zurück zum Zitat Hori M, Takahashi H, Konno T, Inoue J, Haba T, Sakurada T, Noda T, Fujimoto K (1984) Effect of elcatonin on experimental osteoporosis induced by ovariectomy and low calcium diet in beagles. Nippon Yakurigaku Zasshi 84:91–98PubMed Hori M, Takahashi H, Konno T, Inoue J, Haba T, Sakurada T, Noda T, Fujimoto K (1984) Effect of elcatonin on experimental osteoporosis induced by ovariectomy and low calcium diet in beagles. Nippon Yakurigaku Zasshi 84:91–98PubMed
9.
Zurück zum Zitat Yoshikawa S, Shiba M, Hoshino T, Igarashi M, Orimo H, Sakuma A, Tsuyama N (1983) Effect of eel calcitonin derivative(elcatonin) in osteoporosis. Nippon Seikeigeka Gakkai Zasshi 57:1717–1728PubMed Yoshikawa S, Shiba M, Hoshino T, Igarashi M, Orimo H, Sakuma A, Tsuyama N (1983) Effect of eel calcitonin derivative(elcatonin) in osteoporosis. Nippon Seikeigeka Gakkai Zasshi 57:1717–1728PubMed
10.
Zurück zum Zitat Sato M, Rippy MK, Bryant HU (1996) Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissue in ovariecyomized rat. FASEB J 10:905–912PubMed Sato M, Rippy MK, Bryant HU (1996) Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissue in ovariecyomized rat. FASEB J 10:905–912PubMed
11.
Zurück zum Zitat Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480PubMedCrossRef Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480PubMedCrossRef
12.
Zurück zum Zitat Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14:969–979PubMedCrossRef Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14:969–979PubMedCrossRef
13.
Zurück zum Zitat Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2042–2051PubMedCrossRef Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2042–2051PubMedCrossRef
14.
Zurück zum Zitat Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429–436PubMedCrossRef Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429–436PubMedCrossRef
15.
Zurück zum Zitat Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246PubMedCrossRef Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246PubMedCrossRef
16.
Zurück zum Zitat Cao Y, Mori S, Mashiba T, Kaji Y, Manabe T, Iwata K, Miyamoto Kensaku, Komatsubara S, Yamamoto T (2007) 1α-25-Dihydroxy-2β(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora. Bone 40:132–139PubMedCrossRef Cao Y, Mori S, Mashiba T, Kaji Y, Manabe T, Iwata K, Miyamoto Kensaku, Komatsubara S, Yamamoto T (2007) 1α-25-Dihydroxy-2β(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora. Bone 40:132–139PubMedCrossRef
17.
Zurück zum Zitat Chambers TJ, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:819–824PubMedCrossRef Chambers TJ, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:819–824PubMedCrossRef
18.
Zurück zum Zitat Knopp JA, Diner BM, Blitz M (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281–1290PubMedCrossRef Knopp JA, Diner BM, Blitz M (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281–1290PubMedCrossRef
19.
Zurück zum Zitat Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: Yamagata Osteoporosis Prevention Study. Am J Med 117:549–555PubMedCrossRef Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: Yamagata Osteoporosis Prevention Study. Am J Med 117:549–555PubMedCrossRef
20.
Zurück zum Zitat Fujita T, Fujii Y, Goto B (1997) A three-year comparative trial in osteoporosis treatment: effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15:223–226CrossRef Fujita T, Fujii Y, Goto B (1997) A three-year comparative trial in osteoporosis treatment: effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15:223–226CrossRef
21.
Zurück zum Zitat Orimo H, Morii H, Inoue T (1996) Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14:73–78CrossRef Orimo H, Morii H, Inoue T (1996) Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14:73–78CrossRef
22.
Zurück zum Zitat Aro HT, Wippermann BW, Hodgson SF, Chao EY (1990) Internal remodeling of periosteal new bone during fracture healing. J Orthop Res 8:238–246PubMedCrossRef Aro HT, Wippermann BW, Hodgson SF, Chao EY (1990) Internal remodeling of periosteal new bone during fracture healing. J Orthop Res 8:238–246PubMedCrossRef
23.
Zurück zum Zitat Schenk RK, Hunziker EB (1994) Histologic and ultrastructural features of fracture healing. In: Brington CT, Friedlaender GE, Lane JM (eds) Bone regeneration and repair, 1st edn. American Academy of Orthopedic Surgeons, Rosemont, IL, USA, pp 117–146 Schenk RK, Hunziker EB (1994) Histologic and ultrastructural features of fracture healing. In: Brington CT, Friedlaender GE, Lane JM (eds) Bone regeneration and repair, 1st edn. American Academy of Orthopedic Surgeons, Rosemont, IL, USA, pp 117–146
24.
Zurück zum Zitat Einhorn TA (1998) The cell and molecular biology of fracture healing. Clin Orthop 355S:S7–S21CrossRef Einhorn TA (1998) The cell and molecular biology of fracture healing. Clin Orthop 355S:S7–S21CrossRef
25.
Zurück zum Zitat Frost HM (1998) The biology of fracture healing. Clin Orthop 248:283–309 Frost HM (1998) The biology of fracture healing. Clin Orthop 248:283–309
26.
Zurück zum Zitat McKibbin B (1978) The biology of fracture healing in long bones. J Bone Joint Surg Br 60-B:150–162PubMed McKibbin B (1978) The biology of fracture healing in long bones. J Bone Joint Surg Br 60-B:150–162PubMed
27.
Zurück zum Zitat Ikegame M, Ejiri S, Ozawa H (1994) Histochemical and autoradiographic studies on elcatonin internalization and intracellular movement in osteoclasts. J Bone Miner Res 9:25–37PubMedCrossRef Ikegame M, Ejiri S, Ozawa H (1994) Histochemical and autoradiographic studies on elcatonin internalization and intracellular movement in osteoclasts. J Bone Miner Res 9:25–37PubMedCrossRef
28.
Zurück zum Zitat Meschia M, Brincat M, Barbacini P (1993) A clinical trial on effects of a combination of elcatonin (carbo-calcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 53:17–20PubMedCrossRef Meschia M, Brincat M, Barbacini P (1993) A clinical trial on effects of a combination of elcatonin (carbo-calcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 53:17–20PubMedCrossRef
29.
Zurück zum Zitat Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FAO, Martin TJ (1986) Abundant calcitonin receptors in isolated rat osteoclasts. J Clin Invest 78:355–360PubMedCrossRef Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FAO, Martin TJ (1986) Abundant calcitonin receptors in isolated rat osteoclasts. J Clin Invest 78:355–360PubMedCrossRef
30.
Zurück zum Zitat Suda T, Takahashi N, Martin TJ (1992) Modulation of Osteoclast differentiation. Endocr Rev 13:66–80PubMed Suda T, Takahashi N, Martin TJ (1992) Modulation of Osteoclast differentiation. Endocr Rev 13:66–80PubMed
31.
Zurück zum Zitat Lin HY, Harris TL, Flannery MS, Azuffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish HF, Goldring SR (1991) Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254:1022–1024PubMedCrossRef Lin HY, Harris TL, Flannery MS, Azuffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish HF, Goldring SR (1991) Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254:1022–1024PubMedCrossRef
32.
Zurück zum Zitat Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH (2006) Novel insights into actions of bisphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH (2006) Novel insights into actions of bisphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef
Metadaten
Titel
Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys
verfasst von
Takeshi Manabe
Satoshi Mori
Tasuku Mashiba
Yongping Cao
Yoshio Kaji
Ken Iwata
Satoshi Komatsubara
Tetsuji Yamamoto
Azusa Seki
Hiromichi Norimatsu
Publikationsdatum
01.05.2009
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 3/2009
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-009-0046-x

Weitere Artikel der Ausgabe 3/2009

Journal of Bone and Mineral Metabolism 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.